Affordable muscular dystrophy test may improve diagnosis
This article was originally published in Clinica
An affordable gene sequencing test for the most common form of muscular dystrophy could catch the 35% of cases missed by current genetic tests.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.